NAV

MN-305

Identification

Generic Name
MN-305
DrugBank Accession Number
DB05339
Background

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 379.835
Monoisotopic: 379.118650526
Chemical Formula
C19H22ClNO5
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.

TargetActionsOrganism
U5-hydroxytryptamine receptor 1ANot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzo-1,4-dioxanes. These are heterocyclic compounds containing a benzene ring fused to a 1,4-dioxane ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxanes
Sub Class
Benzo-1,4-dioxanes
Direct Parent
Benzo-1,4-dioxanes
Alternative Parents
Benzodioxoles / Alkyl aryl ethers / Para dioxins / Benzenoids / Oxacyclic compounds / Dialkylamines / Acetals / Organopnictogen compounds / Hydrochlorides / Hydrocarbon derivatives
Substituents
Acetal / Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Benzenoid / Benzo-1,4-dioxane / Benzodioxole / Ether / Hydrocarbon derivative / Hydrochloride
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
F0WKFYPQL8
CAS number
Not Available
InChI Key
GGNCUSDIUUCNKE-RSAXXLAASA-N
InChI
InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
IUPAC Name
[3-(2H-1,3-benzodioxol-5-yloxy)propyl]({[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl})amine hydrochloride
SMILES
Cl.C(CNC[C@H]1COC2=CC=CC=C2O1)COC1=CC2=C(OCO2)C=C1

References

General References
  1. Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S166-71. [Article]
PubChem Compound
198746
PubChem Substance
175426979
ChemSpider
172022

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0729 mg/mLALOGPS
logP2.43ALOGPS
logP2.51Chemaxon
logS-3.7ALOGPS
pKa (Strongest Basic)9.1Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area58.18 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity90.59 m3·mol-1Chemaxon
Polarizability37.06 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9919
Blood Brain Barrier+0.8608
Caco-2 permeable-0.5296
P-glycoprotein substrateSubstrate0.6609
P-glycoprotein inhibitor IInhibitor0.6324
P-glycoprotein inhibitor IIInhibitor0.6917
Renal organic cation transporterNon-inhibitor0.5443
CYP450 2C9 substrateNon-substrate0.8682
CYP450 2D6 substrateNon-substrate0.5908
CYP450 3A4 substrateNon-substrate0.5468
CYP450 1A2 substrateInhibitor0.847
CYP450 2C9 inhibitorNon-inhibitor0.8063
CYP450 2D6 inhibitorInhibitor0.6393
CYP450 2C19 inhibitorNon-inhibitor0.5995
CYP450 3A4 inhibitorInhibitor0.7406
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7527
Ames testNon AMES toxic0.5577
CarcinogenicityNon-carcinogens0.9219
BiodegradationNot ready biodegradable0.9284
Rat acute toxicity2.6018 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6893
hERG inhibition (predictor II)Non-inhibitor0.5399
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-177.9576
predicted
DeepCCS 1.0 (2019)
[M+H]+180.3156
predicted
DeepCCS 1.0 (2019)
[M+Na]+187.53258
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. 5-hydroxytryptamine receptor 1A
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da

Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52